QP Release of Drug Products: What Changes When You Move from Clinical Supply to Commercial Batches

Qualified Person certifying commercial drug product batch in GMP facility during transition from clinical supply to commercial manufacturing

Your company has supplied EU clinical trials with investigational medicinal products (IMPs), and you now have, or expect, an EU marketing authorisation (MA). In QP release of drug products for commercial supply, a qualified person (QP) certifies each batch. It uses a different reference, a different legal basis and a different sequence from IMP release. This post sets out what changes and what to put in place before your first commercial batch.

Key Takeaways

  • For commercial batches, the QP certifies against the marketing authorisation, not the trial application and product specification file.
  • The sponsor’s regulatory release to trial sites is an IMP step. For commercial batches, Annex 16 requires QP certification of each batch in the EU before release for sale or supply.
  • Imported batches must be tested in a Member State. Where the EU has a mutual recognition agreement (MRA) or similar agreement with the exporting country and the controls were done there, the QP may be relieved of that responsibility.
  • Before certifying, the QP must ensure, among other points, that the supply chain is documented (preferably as a diagram), audit reports are available, and technical agreements and distribution arrangements are in place.

QP release of drug products: the short answer

For a commercial product, the QP works under Article 51 of Directive 2001/83/EC. For a product made in a Member State, Article 51(1)(a) requires the QP to secure that each batch has been manufactured and checked “in accordance with the requirements of the marketing authorization”. Under Article 51(3), the QP “must certify in a register or equivalent document provided for that purpose, that each production batch satisfies the provisions of this Article”.

Annex 16 of the EU good manufacturing practice (GMP) guide, the EU guidance on QP certification, sets the timing in section 1.1: “Each batch of finished product must be certified by a QP within the EU before being released for sale or supply in the EU or for export.”

So QP release of a commercial batch rests on the MA, the Directive and Annex 16. Our QP release for drug products page describes the service for commercial batches.

What changes when you move from clinical to commercial supply?

For IMPs, the QP certifies each batch made in or imported into the EU under Article 62(1) of Regulation (EU) No 536/2014, with the exceptions covered in our clinical trials post. Under Article 12 of Commission Delegated Regulation (EU) 2017/1569, the QP verifies that each batch was made and checked in line with the information in the trial application. The Commission guideline on GMP for IMPs says the information in the product specification file (PSF) “should form the basis for assessment of the suitability for certification and release of a particular batch by the qualified person”. Our post on QP release for clinical trials covers that side in full.

The table compares the two routes for the same company.

IMP releaseCommercial release
Reference the QP certifies againstInformation in the trial application; the PSF is the basis of the assessmentThe marketing authorisation, including its finished product specification
Legal basisRegulation (EU) No 536/2014, Article 62(1); Delegated Regulation (EU) 2017/1569, Article 12Directive 2001/83/EC, Article 51; Annex 16
After QP certificationThe sponsor’s regulatory release to the trial sitesRelease for sale or supply, which Annex 16 allows only after QP certification
Imported batchesMade to quality standards at least equivalent to EU GMP; see our clinical trials postTested in a Member State; under an MRA or similar agreement, the QP may be relieved of this (Article 51(2))
Safety featuresNot part of this comparisonAffixed to the packaging, where appropriate, for human medicines placed on the EU market

The sponsor’s regulatory release is an IMP step

For IMPs, the EMA guideline on sponsor responsibilities for handling and shipping IMPs (EMA/INS/GMP/258937/2022) says release “consists of the batch certification by the Qualified Person (QP) followed by the regulatory release of the IMP by the sponsor to the sites”.

That second step is defined for IMPs and trial sites. For commercial batches, Annex 16 section 1.1 requires QP certification of each batch before it is “released for sale or supply”. For products made outside the EU, section 1.5 says “physical importation and certification are the final stages of manufacturing which precede the transfer to saleable stock of the batch.”

The marketing authorisation sets the terms

For commercial drug product supply, the MA is the document the QP checks each batch against. Annex 16 section 1.7 lists what the QP must ensure before certifying, and three points tie the batch to the MA:

  • Sites (1.7.4). “All sites of manufacture, analysis and certification are compliant with the terms of the MA for the intended territory.”
  • Activities (1.7.5). “All manufacturing activities and testing activities are consistent with those described in the MA.”
  • Test results (1.7.13). “Finished product quality control (QC) test data complies with the Finished Product Specification described in the MA”.

Article 51(1) of the Directive points the same way. Both its paragraph (a), for products made in a Member State, and its paragraph (b), for products from third countries, measure the batch against the requirements of the MA.

Your certification site is part of the MA

The sites themselves are registered in the MA. The EMA guidance on the QP declaration template (EMA/196292/2014) says a QP declaration on the active substance is required with new MA applications, renewals and “submissions of relevant quality variations, concerning changes (addition or replacement) to the manufacturer of a starting material and / or to the registered manufacturer(s) of the active substance, finished product or batch importation/certification sites”.

In plain terms, your batch importation and certification sites are named in the MA, and adding or replacing one is a quality variation. Choose the certifying site with that in mind.

Imported commercial batches: physical importation, testing and certification

If your product is made outside the EU, Annex 16 section 1.5 treats physical importation and certification as the final stages of manufacturing before the batch moves to saleable stock. Importation needs a manufacturer’s/importer’s authorisation (MIA); our page on EU pharmaceutical importation under an MIA covers the import side.

Testing in a Member State

Article 51(1)(b) applies to products “coming from third countries, irrespective of whether the product has been manufactured in the Community”. Each production batch must have undergone in a Member State “a full qualitative analysis, a quantitative analysis of at least all the active substances and all the other tests or checks necessary to ensure the quality of medicinal products in accordance with the requirements of the marketing authorisation.”

Annex 16 section 1.5.4 places this on the certifying QP “Unless an MRA or similar agreement is in place between the EU and the exporting country”. Article 51(2) covers the case where such arrangements exist and the controls are carried out in the exporting country: “the qualified person may be relieved of responsibility for carrying out those controls.” The word is “may”, so check how any agreement applies to your product before you plan on it.

Sampling, and supply to other Member States

Samples may be taken after arrival in the EU or, with a technically justified approach documented in the company’s quality system, at the third-country site (section 1.5.5). A batch controlled in one Member State is exempt from the controls in another when it is “accompanied by the control reports signed by the qualified person” (Article 51(1)). For the detail on QP batch release of imported products, see our guide to QP certification and batch release under Annex 16.

Safety features on commercial packs

Commercial packs add a packaging check. Under the second subparagraph of Article 51(1), the QP “shall in the case of medicinal products intended to be placed on the market in the Union, ensure that the safety features referred to in point (o) of Article 54 have been affixed on the packaging.” Annex 16 section 1.7.21 repeats this for medicinal products for human use and adds the words “where appropriate”.

What the certifying QP needs from you before the first commercial batch

Annex 16 section 1.7 lists points the QP must ensure before certifying. It says these tasks “may be delegated to appropriately trained personnel or third parties”, and that the QP “will need to rely on the pharmaceutical quality system”. If you use external QP release services, agree with them which of these you provide:

  • A documented supply chain. Under section 1.7.2, “The entire supply chain of the active substance and medicinal product up to the stage of certification is documented and available for the QP.” It “should preferably be in the format of a comprehensive diagram”.
  • Audit reports. Section 1.7.3 requires that all audits of the sites that manufacture and test the product, and of those that make the active substance, have been carried out “and that the audit reports are available to the QP performing the certification.”
  • MA details and the finished product specification. The QP checks sites, activities and QC results against them (sections 1.7.4, 1.7.5 and 1.7.13).
  • Technical agreements. Section 1.7.18: “The required technical agreements are in place.”
  • A formally agreed document if QP responsibilities are shared. Section 1.4.3: “Any sharing of responsibilities amongst QPs in relation to compliance of a batch must be defined in a document formally agreed by all parties.”
  • Distribution and shipment arrangements. Section 1.7.20: “The appropriate arrangements for distribution and shipment are in place.”

Our post on how long batch release takes covers what affects timing for commercial products and IMPs.

How Inglasia Can Help

Inglasia’s QP release for drug products service covers QP release of finished medicinal products for commercial supply in the EU, with documentation review, compliance verification and final QP approval of each batch. It is separate from IMP release and from import licensing under an MIA. To discuss your first commercial batches, contact our team.

Categories :
Share it :

Leave a Reply

Your email address will not be published. Required fields are marked *